MarketBeat
16 Sept 2026, 05:02 UTC · 2h ago
Verdict
Headline takes no side. We score AMGN +0.80 across five claims — strongly bullish.
+0.80strongly bullish
More positive than 88% of ticker scores this week
What the story claims
5 claims · scored −1 bearish … +1 bullish · 1 new · 4 priced in
The DeLLphi-305 phase III study showed IMDELLTRA plus durvalumab provided statistically significant improvement in overall survival and progression-free survival for first-line extensive-stage small-cell lung cancer.
Priced inreported during a conference, not as a primary announcement
So whatExpansion into first-line maintenance targets a combined U.S. addressable population of 28,000 patients.
More positive than 91% of claims this week
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
Amgen completed enrollment in MariTide's obstructive sleep apnea phase III studies at the end of August.
Newstated enrollment completed 'at the end of August'
So whatCompletion of this arm accelerates the timeline toward the estimated dozen phase III trials in the obesity program.
More positive than 85% of claims this week
Two phase III studies of dazodalibep in Sjögren’s disease are on track to report results in the second half of the year.
Priced instanding guidance on trial timelines
More positive than 77% of claims this week
The FDA approved an IMDELLTRA label update reducing required monitoring for the first two doses from 22-24 hours to 6-8 hours.
Priced inreported as a completed FDA action
So whatLowering the monitoring burden by ~15 hours per dose significantly reduces clinic resource requirements, likely increasing adoption rates.
More positive than 66% of claims this week
Amgen's six growth drivers grew 26% year over year in Q2 and represented nearly 70% of product sales.
Priced inanalysis of Q2 results
So whatWith quarterly revenue exceeding $10 billion, these drivers contributed ~$7 billion to the top line.
More positive than 55% of claims this week
Which stocks this story touches
More positive than 88% of ticker scores this week
Strong quarterly revenue growth, positive Phase III clinical trial results for multiple drugs, and a clear growth strategy.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
1d ago
—
AMGN hasn't traded since this ran. Last close $375.65 (Sep 15); the reaction starts at the next open.
AMGN chart →
